As interest in the suprachoroidal (SC) space grows, delivery devices have become the frontline challenge in getting therapies to their target. From microneedles to catheter-assisted injectors, a range of tools are emerging but none without trade-offs.

• Explore how microneedles, tangential injectors, and catheter-based systems differ in precision, invasiveness, and adaptability for posterior segment access
• Innovations in injector geometry and deployment angle are aiming to balance depth control with patient comfort and procedural simplicity
• Success hinges on aligning therapeutic goals with delivery depth, spread, and reach, especially in gene therapy and posterior disease, where IVT often falls short and subretinal carries surgical risk
• Strategic collaboration across device makers, formulation teams, and clinical partners is critical to avoiding translational misfires and maximizing therapeutic potential